CB-183,315

DRUG2 trials

Sponsors

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Conditions

Clostridium Difficile InfectionDiarrhea

Phase 2

Study of CB-183,315 in Participants With Clostridium Difficile Infection

CompletedNCT01085591

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Clostridium Difficile Infection, Diarrhea

Start: 2010-04-01End: 2011-05-13Updated: 2018-09-11

Phase 3

A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)

CompletedNCT01598311

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Clostridium Difficile Infection

Start: 2012-05-16End: 2015-08-25Updated: 2022-08-22

Related Papers

Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities

Journal of Antimicrobial Chemotherapy2020-07-307 citations

Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial.

2017-12-0155 citations

Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.

2016-07-1735 citations